About seller
OBJECTIVES To develop a clinical guideline for structured assessment and uniform reporting of congenital lung abnormalities (CLA) on Computed Tomography (CT)-scans. MATERIALS AND METHODS A systematic literature search was conducted for articles describing CT-scan abnormalities of congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), congenital lobar emphysema (CLE) and bronchogenic cyst (BC). A structured report using objective features of CLA was developed after consensus between a pediatric pulmonologist, radiologist and surgeon. RESULTS Of 1581 articles identified, 158 remained after title-abstract screening by two independent reviewers. AMG-193 research buy After assessing full-texts, we included 28 retrospective cohort-studies. Air-containing cysts and soft tissue masses are described in both CPAM and BPS while anomalous arterial blood supply is only found in BPS. Perilesional low-attenuation areas, atelectasis and mediastinal shift may be found in all aforementioned abnormalities and can also be seen in CLE as a cause of a hyperinflated lobe. We have developed a structured report, subdivided into five sections Location & Extent, Airway, Lesion, Vascularization and Surrounding tissue. CONCLUSIONS CT-imaging findings in CLA are broad and nomenclature is variable. Overlap is seen between and within abnormalities, possibly due to definitions often being based on pathological findings, which is an unsuitable approach for CT imaging. We propose a structured assessment of CLA using objective radiological features and uniform nomenclature to improve reporting. There are multiple indications for luminal imaging of the colon. From assessment of known disease, to diagnosing new pathology; intra-luminal visualisation is the mainstay of gastrointestinal diagnosis. Colonoscopy and radiological imaging are currently the most frequently deployed diagnostic methods. However, both have an associated risk profile, have significant resource pressures and are not universally tolerated. Colon capsule endoscopy (CCE) offers an adjunct to these diagnostic options. In this narrative review the utility of CCE is described. Its current uses, potential benefits and future developments are also discussed. Crown All rights reserved.BACKGROUND Postoperative healthcare cost and use among patients with and without preoperative mental health illness are not well known. OBJECTIVE This study compared total healthcare spending and use (emergency department [ED] visits and inpatient admissions) after 1 year post operation of those with and without preoperative mental health disorders. SETTING United States. METHODS Mental illness disorders were identified using International Classification of Disease-9/10 diagnosis codes in a statewide bariatric surgery registry and in claims databases that were linked to identify the study cohort. Generalized linear regression and zero-inflated negative binomial regression were used for the healthcare cost and use outcomes. RESULTS Among 3580 registry patients with private insurance, 1610 patients with continuous enrollment and without missing body mass index data were included. Among patients, 56.8% (n = 915) had diagnosed mental health disorders before surgery. Those with mental illness spent more in total cost than those without mental illness (unstandardized coefficient = $18,513, P value less then .01) in the first year after surgery. Those with mental illness had a 73% higher rate in ED visits (P value less then .01), 83% higher rate in preventable ED use (P value less then .01), and a 101% higher rate in hospital admissions (P value less then .01) than those without mental illness. CONCLUSIONS Patients with mental health diagnoses before having bariatric surgery appear to have significant positive association with surgical outcomes relating to postsurgical healthcare cost and utilization. Greater postsurgical surveillance may be warranted for bariatric surgery patients with preoperative mental illness to reduce postoperative ED visits and inpatient admissions. BACKGROUND With improved methods of identification and treatment, the numbers of cancer survivors are increasing. Weight loss is encouraged to reduce recurrence. After cancer treatment, will survivors respond to weight change and receive the benefits of bariatric surgery? OBJECTIVE To compare weight loss after bariatric surgery of patients treated for cancer with those never diagnosed with cancer. SETTING The 10 surgical centers participating in the Longitudinal Assessment of Bariatric Surgery (LABS2). METHODS A retrospective review of the LABS database of 2458 participants was completed to determine which patients had answered the question that they had been told they had cancer with a positive response. Cancer survivors were compared for body mass index (calculated as weight in kilograms divided by height in meters squared) at baseline and 1, 3, 5, and 7 years after bariatric surgery with those who responded negatively to this question. Descriptive statistics, Fisher's exact tests, 2-sample independent t tests, Wilcoxon rank sum tests, and multiple linear regression were used. RESULTS Groups were significantly different in age (P less then .0001) and surgery type (P = .02). Other demographic and clinical comparisons were nonsignificant at the .05 significance level. Cancer survivors demonstrated less weight loss at 1 year (P = .0001). Over 7 years, there was no significant difference between the 2 groups. Adjusting for age, sex, baseline body mass index, and surgery type, cancer history was not found to be significant predictor of body mass index change 1-year postbariatric surgery. CONCLUSIONS Patients treated for cancer are not different than the general population in their capacity for long-term weight loss with surgical assistance. In recent years the oxysterol species cholestane-3β, 5α, 6β-triol (C-triol) has found application as a diagnostic biomarker for Niemann-Pick disease type C. Other studies have described increased C-triol in patients with Niemann-Pick disease type A/B and milder increases in lysosomal acid lipase deficiency (LALD), whereas they note normal C-triol levels in Smith-Lemli-Opitz syndrome (SLOS) and familial hypercholesterolaemia (FH) patients. Herein, we review data collected in our laboratory during method evaluation along with 5 years of routine analysis and present findings which differ from those reported by other groups with respect to LALD, SLOS and FH in particular, whilst providing further evidence regarding the clinical sensitivity and specificity of this biomarker, which are difficult to accurately assess. All of our Wolman disease (severe LALD) patients have demonstrated gross elevations of C-triol at diagnosis, with reduction to normal levels after induction of enzyme replacement therapy. In diagnostic specimens from SLOS patients we observed very low or undetectable C-triol levels whereas in post-therapeutic SLOS patients demonstrated normalised levels; we also describe a homozygous FH patient in which C-triol is significantly elevated.